BofA lowered the firm’s price target on RxSight (RXST) to $9 from $18 and keeps an Underperform rating on the shares. The results of the last two quarters raise concerns about near-term adoption and it is hard to be confident that the guide is derisked as RxSight does not appear to have great visibility, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight downgraded to Perform from Outperform at Oppenheimer
- RxSight price target lowered to $9 from $17 at Stifel
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo